STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Retirement of Company Secretary		10/12/13	61.59KB	Share
SPL	Appendix 3B		06/12/13	138.27KB	Share
SPL	Change of Director's Interest Notice		06/12/13	70.42KB	Share
SPL	Appendix 3B		06/12/13	141.6KB	Share
SPL	Initial Director's Interest Notice		05/12/13	62.64KB	Share
SPL	Appointment of Director		05/12/13	112.78KB	Share
SPL	Appendix 3B		02/12/13	98.97KB	Share
SPL	Results of Meeting		22/11/13	42.67KB	Share
SPL	AGM Chair and CEO presentation		22/11/13	2.69MB	Share
SPL	Withdrawal of resolution at AGM		22/11/13	113.14KB	Share
SPL	Starpharma new Board appointment		11/11/13	117.01KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	28/10/13	142.3KB	Share
SPL	Starpharma Dendrimer-Docetaxel eliminates neutropenia	PRICE SENSITIVE	24/10/13	152.32KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		17/10/13	536.62KB	Share
SPL	Reduced neurotoxicity - SPL's dendrimer enhanced oxaliplatin	PRICE SENSITIVE	14/10/13	218.48KB	Share
SPL	Change of Director's Interest Notice		02/10/13	70.9KB	Share
SPL	Appendix 3B		02/10/13	91.23KB	Share
SPL	Date of AGM		23/09/13	60.5KB	Share
SPL	Appendix 3B		20/09/13	85.85KB	Share
SPL	SPL Signs Priostar Agrochemical Partnership with Gowan	PRICE SENSITIVE	16/09/13	84.01KB	Share
SPL	Dendrimer-Oxaliplatin shows better anti-cancer efficacy	PRICE SENSITIVE	11/09/13	270.16KB	Share
SPL	Appendix 3B		02/09/13	87.32KB	Share
SPL	Annual report and full year financial results	PRICE SENSITIVE	26/08/13	1.8MB	Share
SPL	Change in substantial holding		16/08/13	58.58KB	Share
SPL	Presenting at Canaccord Genuity Annual Growth Conference		14/08/13	1.26MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	25/07/13	141.88KB	Share
SPL	Starpharma appoints Business Development executive		17/07/13	105.66KB	Share
SPL	Appendix 3B		12/07/13	93.52KB	Share
SPL	ARC grant for Starpharma's targeted drug delivery	PRICE SENSITIVE	11/07/13	111.8KB	Share
SPL	Change in substantial holding		19/06/13	89.64KB	Share
SPL	Appendix 3B		19/06/13	88.09KB	Share
SPL	Starpharma presenting at Nomura Asia Equity Forum		11/06/13	2.1MB	Share
SPL	Change of Director's Interest Notice - J Fairley		06/06/13	72.15KB	Share
SPL	Shareholder Update May 2013		27/05/13	1.53MB	Share
SPL	Change in substantial holding		22/05/13	93.4KB	Share
SPL	Change in substantial holding		21/05/13	92.43KB	Share
SPL	Starpharma Boardroom Radio Interview		21/05/13	61.68KB	Share
SPL	Presenting at Goldman Sachs Emerging Companies conference		15/05/13	2.09MB	Share
SPL	SPL's dendrimer a potential viral conjunctivitis treatment	PRICE SENSITIVE	13/05/13	67.83KB	Share
SPL	Form604 Notice of change of interests of substantial holder		01/05/13	59.75KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	24/04/13	139.97KB	Share
SPL	Starpharma Granted New Drug Delivery Patents	PRICE SENSITIVE	17/04/13	150.5KB	Share
SPL	Change of Director's Interest Notice		08/04/13	33.09KB	Share
SPL	Form604 Notice of change of interests of substantial holder		08/04/13	68.3KB	Share
SPL	SPL and Makhteshim Agan Priostar agrochemical collaboration		13/03/13	79.95KB	Share
SPL	Change of Director's Interest Notice		08/03/13	77.86KB	Share
SPL	Dendrimers improve anticancer efficacy lung metastasis model	PRICE SENSITIVE	04/03/13	215.35KB	Share
SPL	Half Yearly Report and Accounts	PRICE SENSITIVE	14/02/13	1.77MB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/13	109.65KB	Share
SPL	Appendix 3B		17/01/13	77.1KB	Share
SPL	Shareholder Update December 2012		19/12/12	1.71MB	Share
SPL	Change of Director's Interest Notice - J Fairley		17/12/12	34.03KB	Share
SPL	Appendix 3B		17/12/12	90.16KB	Share
SPL	Starpharma appoints experienced Business Development VP		17/12/12	95.59KB	Share
SPL	Change of Director's Interest Notice - Peter Bartels		13/12/12	69.84KB	Share
SPL	Change of Director's Interest Notice - Richard Hazleton		11/12/12	69.83KB	Share
SPL	Change of Director's Interest Notice - Jackie Fairley		11/12/12	69.49KB	Share
SPL	Form604 Notice of change of interests of substantial holder		11/12/12	62.29KB	Share
SPL	Change of Director's Interest Notice		10/12/12	69.84KB	Share
SPL	Change of Director's Interest Notice		07/12/12	38.35KB	Share
SPL	SPL docetaxel superior to Taxotere across multiple cancers	PRICE SENSITIVE	06/12/12	162.93KB	Share
SPL	Change of Directors Interest Notice		03/12/12	68.83KB	Share
SPL	Final Director's Interest Notice		03/12/12	60.52KB	Share
SPL	Results of Meeting		30/11/12	36.01KB	Share
SPL	AGM Chair address and CEO presentation		30/11/12	1.89MB	Share
SPL	Resignation of Director Mr Ross Dobinson		29/11/12	94.98KB	Share
SPL	Phase 3 study results - investor conference calls		28/11/12	80.65KB	Share
SPL	VivaGel phase 3 study results	PRICE SENSITIVE	28/11/12	158.2KB	Share
SPL	Trading Halt	PRICE SENSITIVE	28/11/12	114.97KB	Share
SPL	Form604 Notice of change of interests of substantial holder		23/11/12	70.99KB	Share
SPL	Starpharma to recoup $6 million cash for overseas R&D	PRICE SENSITIVE	22/11/12	95.79KB	Share
SPL	Starpharma presenting at Bell Potter LifeScience Conference	PRICE SENSITIVE	01/11/12	2.39MB	Share
SPL	Starpharma awarded Janssen 2012 Company of the Year award		01/11/12	87.32KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/12	236.44KB	Share
SPL	New formulations show further improvement in crop protection	PRICE SENSITIVE	30/10/12	269.94KB	Share
SPL	Starpharma's docetaxel demonstrates targeted tumour delivery	PRICE SENSITIVE	29/10/12	365.51KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		22/10/12	625.91KB	Share
SPL	VivaGel BV Phase 3 trials - recruitment complete	PRICE SENSITIVE	18/10/12	125.47KB	Share
SPL	Change of Director's Interest Notice		05/10/12	33.75KB	Share
SPL	Appendix 3B		05/10/12	71.14KB	Share
SPL	Date of Annual General Meeting		27/09/12	117.83KB	Share
SPL	Appendix 3B		18/09/12	65.34KB	Share
SPL	Appendix 3B		13/09/12	74.87KB	Share
SPL	Starpharma signs cancer drug agreement with AstraZeneca	PRICE SENSITIVE	06/09/12	114.8KB	Share
SPL	Annual Report and full year financial results	PRICE SENSITIVE	27/08/12	1.71MB	Share
SPL	Appendix 3B		23/08/12	97.5KB	Share
SPL	Appendix 3B		13/08/12	97.46KB	Share
SPL	Shareholder Update - August 2012		08/08/12	1.16MB	Share
NUF +SPL	Starpharma and Nufarm sign crop protection agreement	PRICE SENSITIVE	07/08/12	108.69KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/12	213.33KB	Share
SPL	SPL presenting at Nomura Biotech Investment Conference		24/07/12	1.62MB	Share
SPL	Appendix 3B		16/07/12	97.5KB	Share
SPL	Appendix 3B		11/07/12	2B	Share
SPL	Reports rapid advancement of drug delivery program	PRICE SENSITIVE	03/07/12	152.19KB	Share
SPL	FORM 604 CHANGE OF INTERESTS OF SUB HOLDER		03/07/12	63.65KB	Share
SPL	Full enrolment achieved for BV Phase 2 & first Phase 3 trial	PRICE SENSITIVE	25/06/12	161.92KB	Share
SPL	Starpharma's VivaGel Phase 3 trials 60% enrolled	PRICE SENSITIVE	04/06/12	130.7KB	Share
SPL	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/12	154.88KB	Share
SPL	Change of Director's Interest Notice		24/04/12	31.84KB	Share
SPL	Response to an ASX price query	PRICE SENSITIVE	24/04/12	136.48KB	Share

SPLRetirement of Company Secretary
10/12/13		61.59KB	Share
SPLAppendix 3B
06/12/13		138.27KB	Share
SPLChange of Director's Interest Notice
06/12/13		70.42KB	Share
SPLAppendix 3B
06/12/13		141.6KB	Share
SPLInitial Director's Interest Notice
05/12/13		62.64KB	Share
SPLAppointment of Director
05/12/13		112.78KB	Share
SPLAppendix 3B
02/12/13		98.97KB	Share
SPLResults of Meeting
22/11/13		42.67KB	Share
SPLAGM Chair and CEO presentation
22/11/13		2.69MB	Share
SPLWithdrawal of resolution at AGM
22/11/13		113.14KB	Share
SPLStarpharma new Board appointment
11/11/13		117.01KB	Share
SPLAppendix 4C - quarterly
28/10/13	PRICE SENSITIVE	142.3KB	Share
SPLStarpharma Dendrimer-Docetaxel eliminates neutropenia
24/10/13	PRICE SENSITIVE	152.32KB	Share
SPLNotice of Annual General Meeting/Proxy Form
17/10/13		536.62KB	Share
SPLReduced neurotoxicity - SPL's dendrimer enhanced oxaliplatin
14/10/13	PRICE SENSITIVE	218.48KB	Share
SPLChange of Director's Interest Notice
02/10/13		70.9KB	Share
SPLAppendix 3B
02/10/13		91.23KB	Share
SPLDate of AGM
23/09/13		60.5KB	Share
SPLAppendix 3B
20/09/13		85.85KB	Share
SPLSPL Signs Priostar Agrochemical Partnership with Gowan
16/09/13	PRICE SENSITIVE	84.01KB	Share
SPLDendrimer-Oxaliplatin shows better anti-cancer efficacy
11/09/13	PRICE SENSITIVE	270.16KB	Share
SPLAppendix 3B
02/09/13		87.32KB	Share
SPLAnnual report and full year financial results
26/08/13	PRICE SENSITIVE	1.8MB	Share
SPLChange in substantial holding
16/08/13		58.58KB	Share
SPLPresenting at Canaccord Genuity Annual Growth Conference
14/08/13		1.26MB	Share
SPLAppendix 4C - quarterly
25/07/13	PRICE SENSITIVE	141.88KB	Share
SPLStarpharma appoints Business Development executive
17/07/13		105.66KB	Share
SPLAppendix 3B
12/07/13		93.52KB	Share
SPLARC grant for Starpharma's targeted drug delivery
11/07/13	PRICE SENSITIVE	111.8KB	Share
SPLChange in substantial holding
19/06/13		89.64KB	Share
SPLAppendix 3B
19/06/13		88.09KB	Share
SPLStarpharma presenting at Nomura Asia Equity Forum
11/06/13		2.1MB	Share
SPLChange of Director's Interest Notice - J Fairley
06/06/13		72.15KB	Share
SPLShareholder Update May 2013
27/05/13		1.53MB	Share
SPLChange in substantial holding
22/05/13		93.4KB	Share
SPLChange in substantial holding
21/05/13		92.43KB	Share
SPLStarpharma Boardroom Radio Interview
21/05/13		61.68KB	Share
SPLPresenting at Goldman Sachs Emerging Companies conference
15/05/13		2.09MB	Share
SPLSPL's dendrimer a potential viral conjunctivitis treatment
13/05/13	PRICE SENSITIVE	67.83KB	Share
SPLForm604 Notice of change of interests of substantial holder
01/05/13		59.75KB	Share
SPLAppendix 4C - quarterly
24/04/13	PRICE SENSITIVE	139.97KB	Share
SPLStarpharma Granted New Drug Delivery Patents
17/04/13	PRICE SENSITIVE	150.5KB	Share
SPLChange of Director's Interest Notice
08/04/13		33.09KB	Share
SPLForm604 Notice of change of interests of substantial holder
08/04/13		68.3KB	Share
SPLSPL and Makhteshim Agan Priostar agrochemical collaboration
13/03/13		79.95KB	Share
SPLChange of Director's Interest Notice
08/03/13		77.86KB	Share
SPLDendrimers improve anticancer efficacy lung metastasis model
04/03/13	PRICE SENSITIVE	215.35KB	Share
SPLHalf Yearly Report and Accounts
14/02/13	PRICE SENSITIVE	1.77MB	Share
SPLAppendix 4C - quarterly
30/01/13	PRICE SENSITIVE	109.65KB	Share
SPLAppendix 3B
17/01/13		77.1KB	Share
SPLShareholder Update December 2012
19/12/12		1.71MB	Share
SPLChange of Director's Interest Notice - J Fairley
17/12/12		34.03KB	Share
SPLAppendix 3B
17/12/12		90.16KB	Share
SPLStarpharma appoints experienced Business Development VP
17/12/12		95.59KB	Share
SPLChange of Director's Interest Notice - Peter Bartels
13/12/12		69.84KB	Share
SPLChange of Director's Interest Notice - Richard Hazleton
11/12/12		69.83KB	Share
SPLChange of Director's Interest Notice - Jackie Fairley
11/12/12		69.49KB	Share
SPLForm604 Notice of change of interests of substantial holder
11/12/12		62.29KB	Share
SPLChange of Director's Interest Notice
10/12/12		69.84KB	Share
SPLChange of Director's Interest Notice
07/12/12		38.35KB	Share
SPLSPL docetaxel superior to Taxotere across multiple cancers
06/12/12	PRICE SENSITIVE	162.93KB	Share
SPLChange of Directors Interest Notice
03/12/12		68.83KB	Share
SPLFinal Director's Interest Notice
03/12/12		60.52KB	Share
SPLResults of Meeting
30/11/12		36.01KB	Share
SPLAGM Chair address and CEO presentation
30/11/12		1.89MB	Share
SPLResignation of Director Mr Ross Dobinson
29/11/12		94.98KB	Share
SPLPhase 3 study results - investor conference calls
28/11/12		80.65KB	Share
SPLVivaGel phase 3 study results
28/11/12	PRICE SENSITIVE	158.2KB	Share
SPLTrading Halt
28/11/12	PRICE SENSITIVE	114.97KB	Share
SPLForm604 Notice of change of interests of substantial holder
23/11/12		70.99KB	Share
SPLStarpharma to recoup $6 million cash for overseas R&D
22/11/12	PRICE SENSITIVE	95.79KB	Share
SPLStarpharma presenting at Bell Potter LifeScience Conference
01/11/12	PRICE SENSITIVE	2.39MB	Share
SPLStarpharma awarded Janssen 2012 Company of the Year award
01/11/12		87.32KB	Share
SPLAppendix 4C - quarterly
31/10/12	PRICE SENSITIVE	236.44KB	Share
SPLNew formulations show further improvement in crop protection
30/10/12	PRICE SENSITIVE	269.94KB	Share
SPLStarpharma's docetaxel demonstrates targeted tumour delivery
29/10/12	PRICE SENSITIVE	365.51KB	Share
SPLNotice of Annual General Meeting/Proxy Form
22/10/12		625.91KB	Share
SPLVivaGel BV Phase 3 trials - recruitment complete
18/10/12	PRICE SENSITIVE	125.47KB	Share
SPLChange of Director's Interest Notice
05/10/12		33.75KB	Share
SPLAppendix 3B
05/10/12		71.14KB	Share
SPLDate of Annual General Meeting
27/09/12		117.83KB	Share
SPLAppendix 3B
18/09/12		65.34KB	Share
SPLAppendix 3B
13/09/12		74.87KB	Share
SPLStarpharma signs cancer drug agreement with AstraZeneca
06/09/12	PRICE SENSITIVE	114.8KB	Share
SPLAnnual Report and full year financial results
27/08/12	PRICE SENSITIVE	1.71MB	Share
SPLAppendix 3B
23/08/12		97.5KB	Share
SPLAppendix 3B
13/08/12		97.46KB	Share
SPLShareholder Update - August 2012
08/08/12		1.16MB	Share
NUF +SPLStarpharma and Nufarm sign crop protection agreement
07/08/12	PRICE SENSITIVE	108.69KB	Share
SPLAppendix 4C - quarterly
30/07/12	PRICE SENSITIVE	213.33KB	Share
SPLSPL presenting at Nomura Biotech Investment Conference
24/07/12		1.62MB	Share
SPLAppendix 3B
16/07/12		97.5KB	Share
SPLAppendix 3B
11/07/12		2B	Share
SPLReports rapid advancement of drug delivery program
03/07/12	PRICE SENSITIVE	152.19KB	Share
SPLFORM 604 CHANGE OF INTERESTS OF SUB HOLDER
03/07/12		63.65KB	Share
SPLFull enrolment achieved for BV Phase 2 & first Phase 3 trial
25/06/12	PRICE SENSITIVE	161.92KB	Share
SPLStarpharma's VivaGel Phase 3 trials 60% enrolled
04/06/12	PRICE SENSITIVE	130.7KB	Share
SPLAppendix 4C - quarterly
30/04/12	PRICE SENSITIVE	154.88KB	Share
SPLChange of Director's Interest Notice
24/04/12		31.84KB	Share
SPLResponse to an ASX price query
24/04/12	PRICE SENSITIVE	136.48KB	Share

REFRESH

First 6 7 8 9 10

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Clean energy vehicles with hydrogen production and distribution all under one roof

Prospect Resources continues to advance Mumbezhi project

Leeuwin Metals set to unlock significant gold potential at Marda

Haranga Resources: From uranium in Senegal to gold in the US

Top Stories